Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
11 2020
Historique:
received: 11 02 2019
revised: 23 05 2020
accepted: 28 05 2020
pubmed: 2 7 2020
medline: 22 6 2021
entrez: 2 7 2020
Statut: ppublish

Résumé

Polycystin-1 (PC1) and -2 (PC2), products of the PKD1 and PKD2 genes, are mutated in autosomal dominant polycystic kidney disease (ADPKD). They localize to the primary cilia; however, their ciliary function is in dispute. Loss of either the primary cilia or PC1 or PC2 causes cyst formation. However, loss of both cilia and PC1 or PC2 inhibits cyst growth via an unknown pathway. To help define a pathway, we studied cilium length in human and mouse kidneys. We found cilia are elongated in kidneys from patients with ADPKD and from both Pkd1 and Pkd2 knockout mice. Cilia elongate following polycystin inactivation. The role of intraflagellar transport proteins in Pkd1-deficient mice is also unknown. We found that inactivation of Ift88 (a gene expressing a core component of intraflagellar transport) in Pkd1 knockout mice, as well as in a new Pkd2 knockout mouse, shortened the elongated cilia, impeded kidney and liver cystogenesis, and reduced cell proliferation. Multi-stage in vivo analysis of signaling pathways revealed β-catenin activation as a prominent, early, and sustained event in disease onset and progression in Pkd2 single knockout but not in Pkd2.Ift88 double knockout mouse kidneys. Additionally, AMPK, mTOR and ERK pathways were altered in Pkd2 single knockout mice but only AMPK and mTOR pathway alteration were rescued in Pkd2.Ift88 double knockout mice. Thus, our findings advocate an essential role of polycystins in the structure and function of the primary cilia and implicate β-catenin as a key inducer of cystogenesis downstream of the primary cilia. Our data suggest that modulating cilium length and/or its associated signaling events may offer novel therapeutic approaches for ADPKD.

Identifiants

pubmed: 32610050
pii: S0085-2538(20)30701-8
doi: 10.1016/j.kint.2020.05.049
pii:
doi:

Substances chimiques

TRPP Cation Channels 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1225-1241

Subventions

Organisme : NIDDK NIH HHS
ID : P50 DK074030
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Lina Shao (L)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Nephrology Division, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.

Wassim El-Jouni (W)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Fanwu Kong (F)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Janani Ramesh (J)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Radhe Shantha Kumar (RS)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Xiaogang Shen (X)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Nephrology Division, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.

Jingjing Ren (J)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Nephrology Division, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.

Shruti Devendra (S)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Arianna Dorschel (A)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Maoqing Wu (M)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Ivan Barrera (I)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Azadeh Tabari (A)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Kang Hu (K)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Nephrology Division, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.

Nadeem Haque (N)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Ilyas Yambayev (I)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Shiqi Li (S)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Amresh Kumar (A)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Tapas Ranjan Behera (TR)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Gregory McDonough (G)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Masahito Furuichi (M)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Michael Xifaras (M)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Tzongshi Lu (T)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Rami Mohammad Alhayaza (RM)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Koji Miyabayashi (K)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Qiuling Fan (Q)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Amrendra K Ajay (AK)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Jing Zhou (J)

Harvard Center for Polycystic Kidney Disease Research and Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: jzhou@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH